CosmosID, Inc. Announces Metagenomics Presentations in Clinical Diagnostics, Global "Healthy" Gut Microbiome, Pharmaceutical Discovery, and Water Safety at ASM Microbe 2017

ROCKVILLE, Md., June 1, 2017 /PRNewswire/ -- CosmosID, Inc., a biotechnology company focused on improving life and wellness through unlocking potential of the microbiome, today announced that new findings of research studies employing its highly curated genome database and next-generation sequencing analysis platform will be presented at the American Society for Microbiology Microbe 2017 conference, at the Ernest N. Morial Convention Center June 1 - 5 in New Orleans.

Abstracts from five studies utilizing CosmosID's sequencing and analysis technology will be presented:

    --  Differences in the Stool and Skin Microbiome, Virulence Factor and
        Antimicrobial Resistance Genes in a Private Room versus a Shared Space
        Neonatal Intensive Care Unit (Clinical Diagnostics) Presented by
        Suchitra K. Hourigan, MD, Inova Fairfax Hospital (Virginia), on June 2
        at 5:50 p.m. CT in HMB Track Hub, Exhibit Hall D

    --  The Gut Microbiome: An Advanced Understanding of Microbial Health Across
        Countries and Cultures (Global "Healthy" Gut Microbiome) presented by
        Nur Hasan, Ph.D., Vice President of Research & Development at CosmosID,
        Inc., on June 3 at 12:15 p.m. CT in Exhibit Hall D

    --  SYN-004 (Ribaxamase), a Clinical-Stage, Oral  -Lactamase Therapeutic,
        Mitigates Antibiotic-Mediated Gut Dysbiosis and Reduces Propagation of
        Antibiotic-Resistance Genes in a Porcine Model (Pharmaceutical
        Discovery) presented by Sheila Connelly, Ph.D. Vice President of
        Research at Synthetic Biologics, Inc., on June 4 at 3:00 p.m. CT in Room
        349

    --  Microbial Community Signatures of Unit Processes for Advanced Treated
        Wastewater Determined by Next Generation Sequencing (Water Safety)
        presented by Menu Leddy, Ph.D., Principal Scientist at Orange County
        Water District, on June 2 at 12:45 p.m. CT in Exhibit Hall D

    --  Membrane Bioreactor-Based Wastewater Treatment Plant: Reduction of Viral
        Diversity, Load and Infectious Capacity (Water Safety) presented by
        Raihan Jamut, Ph.D., King Abdullah University of Science and Technology,
        Thuwal, Saudi Arabia, on June 2 at 12:45 p.m. CT in Exhibit Hall D

CosmosID was founded by Dr. Rita Colwell, Distinguished University Professor, Johns Hopkins University Bloomberg School of Public Health and University of Maryland College Park and Chairman and Global Chief Scientific Officer, CosmosID.

About CosmosID

CosmosID(®), based in Rockville, Maryland, is a genomics big data company focused on rapid identification of microorganisms for molecular diagnostics, public health, food safety, agriculture, and environmental applications. The CosmosID platform uses proprietary sequence analysis algorithms to accurately profile all microorganisms in a metagenomic sample employing next-generation DNA sequencing. To learn more please visit www.cosmosid.com and follow us on Twitter at @CosmosID.

Press Contact
CosmosID, Inc.
Jon Ryan, 703-995-9879
162484@email4pr.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cosmosid-inc-announces-metagenomics-presentations-in-clinical-diagnostics-global-healthy-gut-microbiome-pharmaceutical-discovery-and-water-safety-at-asm-microbe-2017-300467068.html

SOURCE CosmosID